Journal of Hepatology
Volume 47, Issue 2 , Pages 174-182 , August 2007

Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

  • Paul J. Pockros

      Affiliations

    • Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 858 554 8040; fax: +1 858 554 8065.
    • ,
  • Dominque Guyader

      Affiliations

    • Clinique Medicale A – Hepatologie, Centre Hospitalier Regionale Universitaire de Pontchaillou, Rennes, France
    • ,
  • Heather Patton

      Affiliations

    • Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, USA
    • Present address: University of California San Diego Medical Center, San Diego, CA, USA.
    • ,
  • Myron J. Tong

      Affiliations

    • Liver Center, Huntington Medical Research Institute, Pasadena, CA, USA
    • ,
  • Terry Wright

      Affiliations

    • Division of Gastroenterology/Hepatology, University of California, San Francisco, CA, USA
    • Present address: Roche Molecular Labs, San Francisco, CA, USA.
    • ,
  • John G. McHutchison

      Affiliations

    • Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, CA, USA
    • Present address: Duke Clinical Research Institute, Durham, NC, USA.
    • ,
  • Tze-Chiang Meng

      Affiliations

    • Medical and Scientific Affairs, 3M Pharmaceuticals, Saint Paul, MN, USA

Received 26 November 2006 ,Revised 5 February 2007 ,Accepted 14 February 2007.

References 

  1. Management of hepatitis C. The National Institutes of Health Consensus Statement. June 10–12, 2002;15:1–41.
  2. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1–16
  3. Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507–556
  4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  6. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  7. Gupta AK, Cherman AM, Tyring SKJ. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg. 2004;8:338–352
  8. Hemmi H, Kaisho T, Sato S, Sanjo H, Hoshino K, Horiuchi T, et al. Small anti-viral compounds activate cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200
  9. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002;3:499
  10. Gordon KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259–1268
  11. Hart OM, Athie-Morales V, O’Conner CM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J Immunol. 2005;175:1636–1642
  12. Caron G, Duluc D, Fremaux I, Pascale J, David C, Gascan H, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-g production by memory CD+ T cells. J Immunol. 2005;175:1551–1557
  13. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302:659–662
  14. Su AI, Pezaki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA. 2002;99:15669–15674
  15. Guidotti LG, Chisari FV. Non-cytolytic control of viral infections by the innate and adaptive immune response. Ann Rev Immunol. 2001;19:65–91
  16. Brennan GL, Kronenberg LH. Automated bioassay of interferons in micro-test plates. Biotechniques. 1983;1:78–82
  17. Lee J, Wu CCN, Lee KJ, Chuang T, Katakura K, Liu Y, et al. Activation of anti-hepatitis C virus responses via toll-like receptor 7. Proc Natl Acad Sci. 2006;103:1828–1833
  18. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother. 2003;47:3846–3852
  19. Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, Balkow S, et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood. 2005;106:2424–2432
  20. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov. 2002;1:797–807
  21. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005;42:724–731
  22. Vollmer J, Rankin R, Hartman H, Jurk M, Samulowitz U, Wader T, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004;48:2314–2317

☆ T.W. declared that she received funding from the manufacturers to carry out the research and she is an advisory board member of Vernalis Ltd. M.J.T. declared that he has no relationship with the manufacturers of the drug involved either in the past or present and he received funding from the manufacturers to carry out the research. He received funding from SC Liver Research Consortium which enabled him to carry out the study. He is an advisory board member of Vernalis, Ltd. J.G.M. declared that he received funding from the sponsor of this study which enabled him to carry out the study and he is an advisory board member of Vernalis Ltd. H.P. declared that she has no relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out the research. She did not receive funding from any source to carry out the study. D.G. declared that she has no relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out the research. She did not receive funding from any source to carry out the study. P.J.P. declared that he has a relationship with the manufacturers of the drug involved either in the past or present and that he received funding from Vernalis, Ltd. which enabled him to carry out the study. He is an advisory board member of Vernalis, Ltd. and 3M Pharmaceuticals.

☆☆ T.C.M. declared that he has a relationship with the manufacturers of the drugs involved either in the past or present and he received funding from the manufacturers to carry out the research. He received funding from Vernalis plc (formerly Vanguard Medica Limited) which enabled him to carry out the study. T.C.M. is an employee of 3M Pharmaceuticals, the manufacturers of resiquimod (R-848). Vernalis plc, formerly Vanguard Medica Limited, funded the conduct of the studies under a joint development agreement with 3M Pharmaceuticals.

PII: S0168-8278(07)00256-5

doi: 10.1016/j.jhep.2007.02.025

Journal of Hepatology
Volume 47, Issue 2 , Pages 174-182 , August 2007

Article Tools

* Image Usage & Resolution